Human Immune Activation by an HSV-Vectored Vaccine
Northern Kentucky University
We developed herpes simplex virus (HSV)-vectored vaccines for hepatitis C virus (HCV). Vaccine-infected human immune cells demonstrated activation by upregulated expression of inflammatory cytokines and chemokines and by enhanced expression of cellular maturation markers. Expression of adhesion molecules and chemokine receptors were altered in a manner consistent with immune activation. The HSV backbone of the vaccine appeared to be the major source of immune activation. While the initial vaccine target was hepatitis C virus, genes from any other infectious virus, such as novel corona viruses, could be inserted into this vaccine vector to generate immunity to that agent.
2020 Celebration of Student Research and Creativity presentation
Hepatitis C virus, Herpes simplex virus, Vaccines